ArticleJournal of virology2001
Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses.Vaccines · 2021Article
- Demystifying particle-based oral vaccines.Expert opinion on drug delivery · 2021Review
- Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?Frontiers in microbiology · 2018Review
- Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcNature communications · 2017Article
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.Vaccines · 2016Review
- Article
- Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.Iranian journal of basic medical sciences · 2012Article
- DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity.Cell & bioscience · 2011Article
- AAV's anatomy: roadmap for optimizing vectors for translational success.Current gene therapy · 2010Article
- Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.Mucosal immunology · 2010Article
- Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.Journal of translational medicine · 2010Article
- Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.Viral immunology · 2009Article
- Biological gene delivery vehicles: beyond viral vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Mucosal immunity and vaccines.Nature medicine · 2005Review
- Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.Journal of virology · 2004Article
- Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.Journal of virology · 2004Article
- Mucosal immunity: overcoming the barrier for induction of proximal responses.Immunologic research · 2004Review
- Efficient intracellular assembly of papillomaviral vectors.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Intestinal mucosa is a portal for many infectious pathogens. Systemic immunization, in general, does not induce a cytotoxic T-lymphocyte (CTL) response at the mucosal surface. Because papillomavirus (PV) naturally infects mucosa and skin, we determined whether PV pseudovirus, i.e., PV-like particles in which unrelated DNA plasmids are packaged, could generate specific mucosal immunity. We found that the pseudovirus that encoded the lymphocytic choriomeningitis virus gp33 epitope induced a stronger CTL response than a DNA vaccine (plasmid) encoding the same epitope given systemically. The virus-like particles that were used to make the pseudoviruses provided an adjuvant effect for induction of CTLs by the DNA vaccine. The PV pseudovirus pseudoinfected mucosal and systemic lymphoid tissues when administered orally. Oral immunization with the pseudovirus encoding human PV type 16 mutant E7 induced mucosal and systemic CTL responses. In comparison, a DNA vaccine encoding E7, when given orally, did not induce a CTL response in intestinal mucosal lymphoid tissue. Further, oral immunization with the human PV pseudovirus encoding E7 protected mice against mucosal challenge with an E7-expressing bovine PV pseudovirus. Thus, PV pseudovirus can be used as a novel vaccine to induce mucosal and systemic CTL responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.